Worthington Enterprises (WOR) upgraded to buy as sales rise, new wins boost growth, and data center revenue expands. Click ...
Burry is the kind of outspoken outcast who makes for a good character in a Michael Lewis book: a neurologist by training who ...
At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 ...
At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.
Indian Defence Review on MSN
Was It a Message From Aliens? SETI’s Legendary ‘Wow!’ Signal Turns Out to Be Even Stronger Than Previously Thought
A legendary signal from deep space, once dismissed by some as statistical noise, has just become even more mysterious.
LinkedIn has launched its ‘Year in Review’ 2025, offering users a personalised recap of career milestones, network growth, ...
Discover groundbreaking advancements in urologic oncology, including new standards for prostate, kidney, and bladder cancer ...
European review finds strong prevention gains alongside workforce shortages and growing hospital drug spending across health systems.
Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...
Rubrik, Inc. (NYSE:RBRK) is one of the AI Stocks on Market Radar. On December 19, Goldman Sachs reiterated its “Buy” rating ...
Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
Both motor and home premiums continued to fall in November 2025, according to the latest General Insurance Price Index from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback